Hematology Frontier Archives - Page 29 of 75

CTI 2024 | Dr. Marion Subklewe Reveals How AdCAR-T Cells Dualistically Enhance the Safety and Precision of AML Treatment

By Lisa Cui 2024.12.05

From November 14th to 17th, 2024, the Cellular Therapy and Immunotherapy Conference (CTI) was grandly held in Hangzhou, China, gathering top experts, scholars, and industry leaders in the field of global cell therapy and immune therapy. The conference served not only as an international platform for academic exchange but also as an important window to showcase the latest scientific research and promote the development of the field. During the conference, "Hematology Frontier" specially invited Dr. Marion Subklewe from the LMU University Hospital , Germany, to share with us the principles, advantages of AdCAR-T cell technology, and the future optimization direction of AML treatment.

CTI 2024 | IACH Chairman Dr. Mohamad Mohty: Updates on the Latest Treatment Advances in GVHD

By Mourabit Halima 2024.12.05

From November 14th to 17th, 2024, the Cellular Therapy and Immunotherapy Conference (CTI) was grandly held in Hangzhou, China, gathering top experts, scholars, and industry leaders in the field of global cell therapy and immune therapy. The conference served not only as an international platform for academic exchange but also as an important window to showcase the latest scientific research and promote the development of the field. During this conference, "Hematology Frontier" specially invited the conference chair and the chairman of the International Academy for Clinical Hematology (IACH), Dr. Mohamad Mohty from Sorbonne University , France, to share his insights on the latest treatment advances in Graft-Versus-Host Disease (GVHD), aiming to provide valuable insights for clinicians and researchers and to explore the future direction of GVHD treatment.

ASH 2024 | Dr. He Huang’s Team Secures 8 Oral Presentations, Showcasing Chinese Excellence on the Global Stage

By Yin, Jiale 2024.12.04

The highly anticipated 66th Annual Meeting of the American Society of Hematology (ASH) will take place in San Diego, USA, from December 7 to 10, 2024. Renowned as one of the largest and most comprehensive international academic events in hematology, the ASH Annual Meeting serves as a premier platform for advancing the frontiers of the discipline. This global gathering attracts thousands of experts and scholars who come together to exchange cutting-edge research and breakthroughs in the field.

CTI 2024 | Professor Li Tang: Promising Horizons for CAR-T and mRNA Gene Therapy

By Mourabit Halima 2024.12.04

From November 14 to 17, 2024, the Cellular Therapy and Immunotherapy Conference (CTI) took place in Hangzhou, China. This global event brought together leading experts, scholars, and industry pioneers in cellular and immune therapies, serving as both an academic platform and a showcase for the latest research breakthroughs. During the conference, Hematology Frontier launched the special column “Professor, Please Answer,” featuring on-the-spot interviews with prominent professors to capture their insights and visions for the future of the field. In this edition, we share the inspiring perspectives of Professor Li Tang from École Polytechnique Fédérale de Lausanne (EPFL), Switzerland.

CTI 2024丨Prof. Xi Zhang: New Developments and Challenges in Chronic Graft-Versus-Host Disease

By Mourabit Halima 2024.12.03

From November 14 to 17, 2024, the Cellular Therapy and Immunotherapy Conference (CTI) took place in Hangzhou, China, bringing together global leaders in cellular and immune therapies. This prestigious event served as a platform for academic exchange and a showcase for cutting-edge research in the field. During the conference, Prof. Xi Zhang from the Department of Hematology at Xinqiao Hospital , Army Medical University shared key insights on chronic graft-versus-host disease (cGVHD).

How I Treat丨Prof. Fengkui Zhang: My Approach to Treating Severe Aplastic Anemia

By Mourabit Halima 2024.12.03

Severe aplastic anemia (AA) remains a significant therapeutic challenge despite progress in its diagnosis and treatment. Issues such as difficulty in donor matching, side effects of immunosuppressive therapy (IST), and suboptimal hematologic responses demand continued exploration of innovative solutions. Prof. Fengkui Zhang of the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences delivered a compelling presentation on treating severe aplastic anemia. In an interview with Hematology Frontier, Prof. Zhang shared insights into managing refractory aplastic anemia and the latest treatment advancements.

2024 Great Wall Hematology Forum丨Prof. Wenming Chen: Integrating Fundamentals and Clinical Practice to Foster Young Talent

By Peter W. PENG 2024.12.03

On November 15–16, 2024, the "Annual Meeting of the Hematology Committee of the Chinese Medical Education Association—Great Wall Hematology Forum" was successfully held in Beijing. This conference brought together leading experts in hematology to discuss advancements in the diagnosis and treatment of hematological diseases, delve into the latest research findings, and explore the future direction of the field. Hematology Frontier had the honor of interviewing Professor Wenming Chen, Chair of the Hematology Committee and Director of the Hematology Department at Beijing Chaoyang Hospital, who shared highlights of the forum, significant achievements in China’s hematology research, and his insights into nurturing young scholars.

CTI 2024丨Dr. He Huang: Exploring Frontiers and Inspiring the Future—In-depth Analysis of the Highlights of the 2024 Cellular Therapy and Immunotherapy

By Lisa Cui 2024.11.28

From November 14 to 17, 2024, the Cellular Therapy and Immunotherapy (CTI) Conference was held in Hangzhou, China. Jointly organized by Zhejiang University, the International Academy for Clinical Hematology (IACH), the Asian Cellular Therapy Organization (ACTO), the Zhejiang Immunological Society, and Cell Research, this grand event was supported by The First Affiliated Hospital of Zhejiang University and Liangzhu Laboratory as host institutions. Oncology Frontier – Hematology Frontier conducted an in-depth interview with the conference chair, Dr. He Huang from The First Affiliated Hospital of Zhejiang University, to gain insight into the latest progress and future trends in the field of cell and immunotherapy.

Dr. Wenyu Shi on Challenges and Strategies for Treating Elderly Patients with DLBCL

By Yin, Jiale 2024.11.17

From October 18 to 20, 2024, the “2024 Jiangsu Provincial Association of Hematology Physicians Annual Meeting,” hosted by the Jiangsu Provincial Association of Hematology Physicians and organized by Taizhou People's Hospital and the First Affiliated Hospital of Nanjing Medical University, took place in Taizhou, Jiangsu. This event focused on standardized diagnosis and treatment of hematological diseases, providing a high-level academic exchange platform for professionals in hematology. We invited Dr. Wenyu Shi, the executive chairman from Affiliated Hospital of Nantong University, to share his insights with Hematology Frontier.

AMN 2024| Prof. Wenming Chen Receives AMN Distinguished Achievement Award, Leading China’s Advances in Multiple Myeloma

By Mourabit Halima 2024.11.16

On October 19, 2024, the 8th Asian Myeloma Network (AMN) Summit was held in Seoul, South Korea. At this event, the International Myeloma Foundation (IMF) hosted the AMN Awards Ceremony. Prof. Wenming Chen from Beijing Chaoyang Hospital, Capital Medical University, received the AMN Distinguished Achievement Award, recognizing his significant contributions to the field of multiple myeloma (MM) and China’s progress in this field. Following the ceremony, Hematology Frontier had the privilege of interviewing Professor Chen. He shared his thoughts on this award, the development of the AMN, and his insights and outlook on the current and future treatment landscape for MM.